{ "run": { "id": "cmnr12ddt022ip658z20khqb9", "region": "US", "assetId": "cmnr12dd9022ep658p9jm6dbh", "ticker": "AMGN", "snapshotId": "cmnr12ddj022gp65853gp5nao", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:19:40.862Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr12ddj022gp65853gp5nao", "assetId": "cmnr12dd9022ep658p9jm6dbh", "asOf": "2026-04-08T20:00:03.000Z", "snapshot": { "asOf": "2026-04-08T20:00:03.000Z", "quote": { "asOf": "2026-04-08T20:00:03.000Z", "open": null, "price": 349.81, "dayLow": 342.35, "volume": 2619999, "dayHigh": 351.33, "currency": "USD", "prevClose": 340, "week52Low": 261.43, "week52High": 391.29 }, "fundamentals": { "pe": 22.840893230984, "beta": 0.442812578724162, "epsTTM": 14.33, "fcfTTM": 7701000000, "growth": { "epsYoy": 0.8805774278215223, "revenueYoy": 0.0995392532312111 }, "sector": "Biological Products, (No Diagnostic Substances)", "margins": { "net": 0.2857142857142857, "gross": 0.1863200125865324, "operating": 0.35946349905601 }, "website": "https://amgen.com/", "industry": "Biotechnology", "pegRatio": 0.259385404500891, "ebitdaTTM": 15653000000, "forwardPe": 14.6381932021467, "marketCap": 150100000000, "totalCash": 9129000000, "totalDebt": 59203000000, "debtEquity": 6.83795333795334, "quickRatio": 0.7336105771116952, "revenueTTM": 25424000000, "companyName": "AMGEN INC", "priceToBook": 2.70508287632303, "currentRatio": 1.139981952999333, "dividendYield": 0.0296888946838138, "returnOnAssets": 0.08018899167641799, "returnOnEquity": 0.890621390621391, "analystOpinions": null, "businessSummary": "Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name \"AMGen\" is a portmanteau of the company's original name, Applied Molecular Genetics.", "enterpriseValue": 226166780000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 31500, "sharesOutstanding": 539067675, "enterpriseToEbitda": 14.44878170318789, "analystTargetMedian": null, "enterpriseToRevenue": 8.89579845814978, "operatingCashflowTTM": 9958000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:19:40.856Z" }, "results": [ { "id": "cmnr12ddw022kp658sd15yq26", "runId": "cmnr12ddt022ip658z20khqb9", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"AMGN\",\"currency\":\"USD\",\"current_price\":349.81,\"target_price_6m\":370,\"target_price_12m\":390,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Forward P/E of ~14.6x undervalues accelerating earnings growth trajectory\",\"MariTide obesity pipeline catalyst could unlock significant long-term value\",\"Horizon Therapeutics integration adding ~10% revenue growth and margin accretion\",\"PEG ratio of 0.26 signals compelling growth-adjusted valuation discount\",\"~3% dividend yield provides downside support amid defensive biotech profile\"],\"key_drivers\":[{\"driver\":\"Horizon Therapeutics revenue integration and synergy realization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"MariTide (maridebart kafugrast) obesity program Phase 3 readouts\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Elevated debt load ($59B) constraining financial flexibility\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"EPS growth acceleration: 88% YoY with forward P/E compression\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Biosimilar competition eroding legacy franchise revenues\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Strong FCF generation ($7.7B TTM) supporting deleveraging path\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Potential IRA drug pricing negotiation impact on key products\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Low beta (0.44) defensive positioning in volatile macro backdrop\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Patent cliffs on Enbrel and other legacy products\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Debt/equity of 6.84x creates significant financial risk if earnings disappoint\",\"MariTide Phase 3 failure would remove key growth narrative\",\"IRA Medicare drug price negotiations could compress margins on key drugs\",\"Biosimilar erosion of Enbrel/Neulasta faster than expected\",\"Credit downgrade risk if deleveraging stalls amid rising rates\",\"Horizon acquisition integration missteps or slower-than-expected synergies\"],\"assumptions\":{\"revenue_cagr_3y\":0.07,\"ebit_margin_target\":0.37,\"wacc\":0.085,\"terminal_multiple\":15.5},\"scenarios\":{\"bear\":{\"target_price\":290,\"prob\":0.2,\"notes\":\"Obesity pipeline setback plus slower deleveraging compresses multiple to 12-13x forward EPS.\"},\"base\":{\"target_price\":390,\"prob\":0.55,\"notes\":\"Steady Horizon integration, ~$24 forward EPS at 16x multiple, gradual deleveraging.\"},\"bull\":{\"target_price\":445,\"prob\":0.25,\"notes\":\"MariTide success plus margin expansion drives $26+ EPS at 17x multiple.\"}},\"method_notes\":\"Blended forward P/E and EV/EBITDA valuation. Forward EPS ~$24 at 16x = ~$384 base. Adjusted for probability-weighted scenarios. High debt load and pipeline binary risks temper confidence to 0.62. PEG of 0.26 supports valuation gap vs biotech peers. Snapshot fields used as-is. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "ai-equity-research-v1", "risks": [ "Debt/equity of 6.84x creates significant financial risk if earnings disappoint", "MariTide Phase 3 failure would remove key growth narrative", "IRA Medicare drug price negotiations could compress margins on key drugs", "Biosimilar erosion of Enbrel/Neulasta faster than expected", "Credit downgrade risk if deleveraging stalls amid rising rates", "Horizon acquisition integration missteps or slower-than-expected synergies" ], "ticker": "AMGN", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady Horizon integration, ~$24 forward EPS at 16x multiple, gradual deleveraging.", "target_price": 390 }, "bear": { "prob": 0.2, "notes": "Obesity pipeline setback plus slower deleveraging compresses multiple to 12-13x forward EPS.", "target_price": 290 }, "bull": { "prob": 0.25, "notes": "MariTide success plus margin expansion drives $26+ EPS at 17x multiple.", "target_price": 445 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.07, "terminal_multiple": 15.5, "ebit_margin_target": 0.37 }, "key_drivers": [ { "driver": "Horizon Therapeutics revenue integration and synergy realization", "impact": "HIGH", "direction": "POS" }, { "driver": "MariTide (maridebart kafugrast) obesity program Phase 3 readouts", "impact": "HIGH", "direction": "POS" }, { "driver": "Elevated debt load ($59B) constraining financial flexibility", "impact": "HIGH", "direction": "NEG" }, { "driver": "EPS growth acceleration: 88% YoY with forward P/E compression", "impact": "HIGH", "direction": "POS" }, { "driver": "Biosimilar competition eroding legacy franchise revenues", "impact": "MED", "direction": "NEG" }, { "driver": "Strong FCF generation ($7.7B TTM) supporting deleveraging path", "impact": "MED", "direction": "POS" }, { "driver": "Potential IRA drug pricing negotiation impact on key products", "impact": "MED", "direction": "NEG" }, { "driver": "Low beta (0.44) defensive positioning in volatile macro backdrop", "impact": "LOW", "direction": "POS" }, { "driver": "Patent cliffs on Enbrel and other legacy products", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended forward P/E and EV/EBITDA valuation. Forward EPS ~$24 at 16x = ~$384 base. Adjusted for probability-weighted scenarios. High debt load and pipeline binary risks temper confidence to 0.62. PEG of 0.26 supports valuation gap vs biotech peers. Snapshot fields used as-is. Not investment advice.", "current_price": 349.81, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E of ~14.6x undervalues accelerating earnings growth trajectory", "MariTide obesity pipeline catalyst could unlock significant long-term value", "Horizon Therapeutics integration adding ~10% revenue growth and margin accretion", "PEG ratio of 0.26 signals compelling growth-adjusted valuation discount", "~3% dividend yield provides downside support amid defensive biotech profile" ], "target_price_6m": 370, "target_price_12m": 390 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 50834, "createdAt": "2026-04-09T05:19:40.862Z", "usage": { "inputTokens": 3592, "outputTokens": 1529, "costUsd": 0.056185 } }, { "id": "cmnr12ddw022np658g5k4ulz4", "runId": "cmnr12ddt022ip658z20khqb9", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity_Research_AI\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"AMGN\",\n \"currency\": \"USD\",\n \"current_price\": 349.81,\n \"target_price_6m\": 360.0,\n \"target_price_12m\": 380.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Robust EPS growth from operational efficiency.\",\n \"High profitability with strong net margins.\",\n \"Steady revenue growth from product portfolio.\",\n \"Significant debt load increasing financial risk.\",\n \"Defensive stock with low beta and dividend.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"EPS Growth YoY\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Revenue Growth\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Net Margin\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Debt to Equity Ratio\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Pipeline Development\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Competitive Pressure\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory Approvals\", \"impact\": \"LOW\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Patent expirations on key drugs.\",\n \"High leverage and interest rate risk.\",\n \"Clinical trial failures in pipeline.\",\n \"Market competition reducing pricing power.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.36,\n \"wacc\": 0.09,\n \"terminal_multiple\": 15.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 320.0, \"prob\": 0.2, \"notes\": \"Downside from pipeline failures or higher costs.\" },\n \"base\": { \"target_price\": 380.0, \"prob\": 0.6, \"notes\": \"Steady execution with moderate growth.\" },\n \"bull\": { \"target_price\": 420.0, \"prob\": 0.2, \"notes\": \"Successful new drug launches and margin expansion.\" }\n },\n \"method_notes\": \"DCF valuation with 8% revenue CAGR, 36% EBIT margin, 9% WACC, 15x terminal multiple. BUY due to 8.6% 12M upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "Equity_Research_AI", "risks": [ "Patent expirations on key drugs.", "High leverage and interest rate risk.", "Clinical trial failures in pipeline.", "Market competition reducing pricing power." ], "ticker": "AMGN", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution with moderate growth.", "target_price": 380 }, "bear": { "prob": 0.2, "notes": "Downside from pipeline failures or higher costs.", "target_price": 320 }, "bull": { "prob": 0.2, "notes": "Successful new drug launches and margin expansion.", "target_price": 420 } }, "confidence": 0.65, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.08, "terminal_multiple": 15, "ebit_margin_target": 0.36 }, "key_drivers": [ { "driver": "EPS Growth YoY", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue Growth", "impact": "MED", "direction": "POS" }, { "driver": "Net Margin", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt to Equity Ratio", "impact": "HIGH", "direction": "NEG" }, { "driver": "Pipeline Development", "impact": "MED", "direction": "POS" }, { "driver": "Competitive Pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory Approvals", "impact": "LOW", "direction": "POS" } ], "method_notes": "DCF valuation with 8% revenue CAGR, 36% EBIT margin, 9% WACC, 15x terminal multiple. BUY due to 8.6% 12M upside. Not investment advice.", "current_price": 349.81, "recommendation": "BUY", "thesis_bullets": [ "Robust EPS growth from operational efficiency.", "High profitability with strong net margins.", "Steady revenue growth from product portfolio.", "Significant debt load increasing financial risk.", "Defensive stock with low beta and dividend." ], "target_price_6m": 360, "target_price_12m": 380 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 356, "createdAt": "2026-04-09T05:19:40.862Z", "usage": { "inputTokens": 2095, "outputTokens": 3665, "costUsd": 0.002126 } }, { "id": "cmnr12ddw022lp658vj1olknw", "runId": "cmnr12ddt022ip658z20khqb9", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Amgen Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"AMGN\",\n \"currency\": \"USD\",\n \"current_price\": 349.81,\n \"target_price_6m\": 365.00,\n \"target_price_12m\": 385.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"MariTide obesity data presents significant upside potential despite intense market competition.\",\n \"Horizon Therapeutics acquisition diversifies revenue and boosts rare disease portfolio growth.\",\n \"Biosimilar competition for legacy drugs like Prolia and Enbrel remains a structural headwind.\",\n \"Strong free cash flow generation of $7.7B TTM supports a solid 3% dividend yield.\",\n \"High debt load of $59.2B requires disciplined capital allocation and limits near-term M&A.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"MariTide clinical data and launch trajectory\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Horizon Therapeutics revenue synergies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Biosimilar erosion on legacy blockbusters\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Repatha and Evenity volume growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Deleveraging and debt reduction progress\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"IRA drug pricing impacts\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Clinical trial failures, particularly in the highly anticipated obesity pipeline (MariTide).\",\n \"Faster-than-expected revenue erosion from biosimilars for Prolia, Xgeva, and Enbrel.\",\n \"Regulatory pricing pressures from the Inflation Reduction Act (IRA) impacting margins.\",\n \"High leverage ratio limiting financial flexibility and increasing interest rate sensitivity.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.38,\n \"wacc\": 0.075,\n \"terminal_multiple\": 13.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 290.00,\n \"prob\": 0.25,\n \"notes\": \"MariTide disappoints in trials and biosimilar erosion accelerates faster than expected.\"\n },\n \"base\": {\n \"target_price\": 385.00,\n \"prob\": 0.55,\n \"notes\": \"Steady growth from rare diseases and moderate commercial success in the obesity pipeline.\"\n },\n \"bull\": {\n \"target_price\": 450.00,\n \"prob\": 0.20,\n \"notes\": \"MariTide achieves best-in-class profile, capturing significant obesity market share.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF and 14.5x forward P/E multiple. The ~10% upside to our 12M target of $385 supports a BUY rating, balanced by pipeline execution risks and high debt levels. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "Amgen Equity Research Model", "risks": [ "Clinical trial failures, particularly in the highly anticipated obesity pipeline (MariTide).", "Faster-than-expected revenue erosion from biosimilars for Prolia, Xgeva, and Enbrel.", "Regulatory pricing pressures from the Inflation Reduction Act (IRA) impacting margins.", "High leverage ratio limiting financial flexibility and increasing interest rate sensitivity." ], "ticker": "AMGN", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady growth from rare diseases and moderate commercial success in the obesity pipeline.", "target_price": 385 }, "bear": { "prob": 0.25, "notes": "MariTide disappoints in trials and biosimilar erosion accelerates faster than expected.", "target_price": 290 }, "bull": { "prob": 0.2, "notes": "MariTide achieves best-in-class profile, capturing significant obesity market share.", "target_price": 450 } }, "confidence": 0.65, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.06, "terminal_multiple": 13.5, "ebit_margin_target": 0.38 }, "key_drivers": [ { "driver": "MariTide clinical data and launch trajectory", "impact": "HIGH", "direction": "POS" }, { "driver": "Horizon Therapeutics revenue synergies", "impact": "MED", "direction": "POS" }, { "driver": "Biosimilar erosion on legacy blockbusters", "impact": "HIGH", "direction": "NEG" }, { "driver": "Repatha and Evenity volume growth", "impact": "MED", "direction": "POS" }, { "driver": "Deleveraging and debt reduction progress", "impact": "MED", "direction": "POS" }, { "driver": "IRA drug pricing impacts", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation based on a 10-year DCF and 14.5x forward P/E multiple. The ~10% upside to our 12M target of $385 supports a BUY rating, balanced by pipeline execution risks and high debt levels. Not investment advice.", "current_price": 349.81, "recommendation": "BUY", "thesis_bullets": [ "MariTide obesity data presents significant upside potential despite intense market competition.", "Horizon Therapeutics acquisition diversifies revenue and boosts rare disease portfolio growth.", "Biosimilar competition for legacy drugs like Prolia and Enbrel remains a structural headwind.", "Strong free cash flow generation of $7.7B TTM supports a solid 3% dividend yield.", "High debt load of $59.2B requires disciplined capital allocation and limits near-term M&A." ], "target_price_6m": 365, "target_price_12m": 385 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 20815, "createdAt": "2026-04-09T05:19:40.862Z", "usage": { "inputTokens": 2458, "outputTokens": 883, "costUsd": 0.015512 } }, { "id": "cmnr12ddv022jp658mkvl0w3e", "runId": "cmnr12ddt022ip658z20khqb9", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"AMGN\",\"currency\":\"USD\",\"current_price\":349.81,\"target_price_6m\":366,\"target_price_12m\":378,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Core portfolio supports resilient cash flow and a near-3% dividend yield.\",\"Horizon assets and pipeline help offset erosion in mature brands.\",\"Forward valuation appears reasonable for Amgen's scale and defensiveness.\",\"High leverage tempers flexibility despite strong EBITDA and cash generation.\",\"Obesity and biosimilar execution add upside, but also material uncertainty.\"],\"key_drivers\":[{\"driver\":\"Rare disease integration\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"MariTide obesity data\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Legacy brand erosion\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Operating margin discipline\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Debt reduction pace\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Biosimilar competition\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Business development\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Drug pricing policy\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"MariTide efficacy or tolerability disappoints\",\"Faster declines in legacy franchises\",\"IRA pricing pressure expands\",\"Leverage stays elevated longer\",\"Horizon integration underdelivers\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.36,\"wacc\":0.085,\"terminal_multiple\":14.5},\"scenarios\":{\"bear\":{\"target_price\":305,\"prob\":0.25,\"notes\":\"Pipeline optionality fades and mature-product erosion outweighs cost control.\"},\"base\":{\"target_price\":378,\"prob\":0.5,\"notes\":\"Steady execution, modest deleveraging, and durable cash flows support mid-single-digit rerating.\"},\"bull\":{\"target_price\":440,\"prob\":0.25,\"notes\":\"Stronger pipeline data and rare-disease growth drive multiple expansion.\"}},\"method_notes\":\"Blended valuation using forward EV/EBITDA and FCF yield, anchored to snapshot quote/fundamentals; external context only for business outlook. No sell-side price targets used. Base case implies ~8% 12M upside, fitting BUY with medium confidence; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Model Recommendation", "risks": [ "MariTide efficacy or tolerability disappoints", "Faster declines in legacy franchises", "IRA pricing pressure expands", "Leverage stays elevated longer", "Horizon integration underdelivers" ], "ticker": "AMGN", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution, modest deleveraging, and durable cash flows support mid-single-digit rerating.", "target_price": 378 }, "bear": { "prob": 0.25, "notes": "Pipeline optionality fades and mature-product erosion outweighs cost control.", "target_price": 305 }, "bull": { "prob": 0.25, "notes": "Stronger pipeline data and rare-disease growth drive multiple expansion.", "target_price": 440 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.06, "terminal_multiple": 14.5, "ebit_margin_target": 0.36 }, "key_drivers": [ { "driver": "Rare disease integration", "impact": "HIGH", "direction": "POS" }, { "driver": "MariTide obesity data", "impact": "HIGH", "direction": "POS" }, { "driver": "Legacy brand erosion", "impact": "HIGH", "direction": "NEG" }, { "driver": "Operating margin discipline", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction pace", "impact": "MED", "direction": "POS" }, { "driver": "Biosimilar competition", "impact": "MED", "direction": "NEG" }, { "driver": "Business development", "impact": "MED", "direction": "POS" }, { "driver": "Drug pricing policy", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended valuation using forward EV/EBITDA and FCF yield, anchored to snapshot quote/fundamentals; external context only for business outlook. No sell-side price targets used. Base case implies ~8% 12M upside, fitting BUY with medium confidence; not investment advice.", "current_price": 349.81, "recommendation": "BUY", "thesis_bullets": [ "Core portfolio supports resilient cash flow and a near-3% dividend yield.", "Horizon assets and pipeline help offset erosion in mature brands.", "Forward valuation appears reasonable for Amgen's scale and defensiveness.", "High leverage tempers flexibility despite strong EBITDA and cash generation.", "Obesity and biosimilar execution add upside, but also material uncertainty." ], "target_price_6m": 366, "target_price_12m": 378 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_063dda5b2d26242c0069d7530f35c4819498554233c2a8b895", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 30532, "createdAt": "2026-04-09T05:19:40.862Z", "usage": { "inputTokens": 2366, "outputTokens": 1726, "costUsd": 0.028305 } }, { "id": "cmnr12ddw022mp658v9vwty9j", "runId": "cmnr12ddt022ip658z20khqb9", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Fundamental Valuation Model\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"AMGN\",\n \"currency\": \"USD\",\n \"current_price\": 349.81,\n \"target_price_6m\": 370,\n \"target_price_12m\": 390,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Core products drive steady revenue and 10% growth\",\n \"Obesity and oncology pipeline offers upside potential\",\n \"Strong FCF supports dividends and R&D investment\",\n \"High debt from acquisitions limits financial flexibility\",\n \"Forward P/E of 14.6x reasonable vs growth outlook\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Pipeline success in obesity\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Patent expirations on legacy drugs\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Revenue CAGR from new launches\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"High debt burden and interest costs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operating margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Biosimilar competition intensity\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Dividend yield attractiveness\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory approval timelines\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Patent cliffs and biosimilar erosion\",\n \"Clinical or regulatory setbacks\",\n \"Debt refinancing in high rate environment\",\n \"Intense competition in key therapeutic areas\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.07,\n \"ebit_margin_target\": 0.37,\n \"wacc\": 0.085,\n \"terminal_multiple\": 16\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 290,\n \"prob\": 0.25,\n \"notes\": \"Pipeline delays and faster erosion hit growth.\"\n },\n \"base\": {\n \"target_price\": 390,\n \"prob\": 0.5,\n \"notes\": \"Steady execution and modest pipeline success.\"\n },\n \"bull\": {\n \"target_price\": 470,\n \"prob\": 0.25,\n \"notes\": \"Blockbuster obesity drug accelerates revenue.\"\n }\n },\n \"method_notes\": \"DCF using 7% revenue CAGR, 8.5% WACC, 16x terminal EV/EBITDA plus peer comps. 11% base upside supports BUY per rubric; balanced bull/bear drivers. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Fundamental Valuation Model", "risks": [ "Patent cliffs and biosimilar erosion", "Clinical or regulatory setbacks", "Debt refinancing in high rate environment", "Intense competition in key therapeutic areas" ], "ticker": "AMGN", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution and modest pipeline success.", "target_price": 390 }, "bear": { "prob": 0.25, "notes": "Pipeline delays and faster erosion hit growth.", "target_price": 290 }, "bull": { "prob": 0.25, "notes": "Blockbuster obesity drug accelerates revenue.", "target_price": 470 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.07, "terminal_multiple": 16, "ebit_margin_target": 0.37 }, "key_drivers": [ { "driver": "Pipeline success in obesity", "impact": "HIGH", "direction": "POS" }, { "driver": "Patent expirations on legacy drugs", "impact": "HIGH", "direction": "NEG" }, { "driver": "Revenue CAGR from new launches", "impact": "HIGH", "direction": "POS" }, { "driver": "High debt burden and interest costs", "impact": "MED", "direction": "NEG" }, { "driver": "Operating margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Biosimilar competition intensity", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend yield attractiveness", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approval timelines", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF using 7% revenue CAGR, 8.5% WACC, 16x terminal EV/EBITDA plus peer comps. 11% base upside supports BUY per rubric; balanced bull/bear drivers. Not investment advice.", "current_price": 349.81, "recommendation": "BUY", "thesis_bullets": [ "Core products drive steady revenue and 10% growth", "Obesity and oncology pipeline offers upside potential", "Strong FCF supports dividends and R&D investment", "High debt from acquisitions limits financial flexibility", "Forward P/E of 14.6x reasonable vs growth outlook" ], "target_price_6m": 370, "target_price_12m": 390 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "7fb02cf9-7818-977b-92ec-eb72e1d1f5d0", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 15108, "createdAt": "2026-04-09T05:19:40.862Z", "usage": { "inputTokens": 2703, "outputTokens": 2655, "costUsd": 0.047934 } } ] } }